0Q15.LSE Abbott Laboratories
- Market cap
- USD 191B
- P/E
- 14.2x
- P/B
- 3.60x
- ROE
- 8.3%
- Dividend yield
- 2.16%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is 0Q15.LSE undervalued?
Graham number0Q15.LSE trades 50.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Abbott Laboratories fundamental analysis
No fundamental analysis for Abbott Laboratories yet.
Abbott Laboratories stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hor…
Full company profileAbbott Laboratories financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Abbott Laboratories annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 43.1B | 43.7B | 40.1B | 42.0B | 44.3B | 44.7B |
| Gross Profit | 24.5B | 24.5B | 22.1B | 23.2B | 25.0B | 25.1B |
| Operating Income | 8.43B | 8.36B | 6.48B | 6.83B | 8.05B | 5.38B |
| EBITDA | - | 12.1B | 10.5B | 10.8B | 12.1B | 9.70B |
| Net Income | 7.07B | 6.93B | 5.72B | 13.4B | 6.52B | 4.31B |
| EPS | 4.01 | 3.99 | 3.30 | 7.74 | 3.76 | 2.47 |
| Balance Sheet | ||||||
| Total Assets | 75.2B | 74.4B | 73.2B | 81.4B | 86.7B | 110B |
| Total Liabilities | 39.2B | 37.5B | 34.4B | 33.5B | 33.9B | 57.7B |
| Shareholders' Equity | 35.8B | 36.7B | 38.6B | 47.7B | 52.1B | 52.1B |
| Cash & Short-term Investments | 9.80B | 9.88B | 6.90B | 7.62B | 8.52B | 6.80B |
| Cash Flow | ||||||
| Operating Cash Flow | 10.5B | 9.58B | 7.26B | 8.56B | 9.57B | - |
| Capital Expenditure | 1.89B | 1.78B | 2.20B | 2.21B | 2.17B | 798M |
| Free Cash Flow | 8.65B | 7.80B | 5.06B | 6.35B | 7.40B | - |
| Ratios | ||||||
| ROE | 19.8% | 18.9% | 14.8% | 28.1% | 12.5% | 8.3% |
| ROA | 9.4% | 9.3% | 7.8% | 16.5% | 7.5% | 3.9% |
| Net Profit Margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% | 9.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Abbott Laboratories dividends
- Dividend yield
- 2.16%
- Forward dividend
- -
- Payout ratio
- 63.1%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 4.12B | 2.37 | 63.1% |
| 2024 | USD 3.84B | 2.22 | 28.6% |
| 2023 | USD 3.56B | 2.05 | 62.1% |
| 2022 | USD 3.31B | 1.90 | 47.7% |
| 2021 | USD 3.20B | 1.82 | 45.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 1, 1998.
Who owns Abbott Laboratories
- Insiders 0.49%
- Institutions 81.81%
- Public & others 17.70%
- Shares outstanding 1.74B
- Free float 1.72B
Abbott Laboratories company profile
- Company name
- Abbott Laboratories
- Ticker
- 0Q15.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 122,000
- Fiscal year end
- December
- Address
- 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400
- Phone
- 224 667 6100
- Website
- abbott.com
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Abbott Laboratories management
10- Mr. Robert B. FordExecutive Chairman & CEO · born 1974
- Mr. Philip P. BoudreauCFO & Executive VP of Finance · born 1973
- Mr. Daniel Gesua Sive SalvadoriExecutive VP and Group President of Established Pharmaceuticals & Nutritional Products · born 1979
- Mr. Christopher J. ScogginsExecutive Vice President of Diabetes Care · born 1970
- Ms. Lisa D. EarnhardtExecutive VP & Group President of Medical Devices · born 1970
- Ms. Sabina EwingSenior VP of Business & Technology Services and Chief Information Officer · born 1974
- Mr. Michael ComillaVice President of Investor Relations.
- Erica L. BattagliaVP and Chief Ethics & Compliance Officer
- Ms. Elizabeth C. CushmanExecutive VP, General Counsel & Secretary · born 1970
- Ms. Melissa BrotzSenior Vice President of Global Marketing & External Affairs